All In Biotech

Drug Trial Radar · NCT05889273

ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)

An Open-label Extension Study to Investigate Safety and Tolerability of ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD).

Last checked: Nov 19, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Jun 1, 2023

Primary completion

Nov 2027

Study completion Dec 2027

Sponsor

Lead sponsor
MapLight TherapeuticsIndustry
Sponsor type
Industry
First posted
Jun 5, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 46 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ML-004-003 is a multi-center, open-label extension study that will enroll approximately 120 adolescent and adult subjects with ASD that have completed study ML-004-002. The primary objective of the study will be to evaluate the safety of ML-004 in subjects with ASD.

Conditions

  • Autism Spectrum Disorder

Interventions

  • ML-004 (IR)/(ER) tabletDrug

    Participants will receive ML-004 once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of occurrence of treatment-emergent adverse events (TEAEs).Time frame: Baseline up to Day 362

Locations

21 sites in 3 countries. Site status is shown where the registry gives one.

  • Harmonex Neuroscience Research

    Dothan, Alabama

  • Southwest Autism Research and Resource Center

    Phoenix, Arizona

  • Cortica Healthcare

    Glendale, California

  • NRC Research Institute

    Orange, California

  • Cortica

    San Rafael, California

  • Yale Child Study Center

    New Haven, Connecticut

  • The Children's Research Institute

    Washington D.C., District of Columbia

  • Abba Medical Group

    Miami, Florida

  • APG Research, LLC

    Orlando, Florida

  • University of South Florida Psychiatry and Behavioral Neurosciences

    Tampa, Florida

  • Neurobehavioral Medicine Group

    Bloomfield Hills, Michigan

  • University of Missouri, Thompson Center for Autism & Neurodevelopment

    Columbia, Missouri

  • Nathan Kline Institute for Psychiatric Research

    Orangeburg, New York

  • Richmond Behavioral Associates

    Staten Island, New York

  • Suburban Research Associates

    Media, Pennsylvania

  • BioBehavioral Research of Austin

    Austin, Texas

  • Road Runner Research, Ltd.

    San Antonio, Texas

  • Family Psychiatry of The Woodlands

    The Woodlands, Texas

  • Brain and Mind Centre

    Camperdown, New South Wales, Australia

  • The Royal Children's Hospital, Murdoch Children's Research Institute

    Parkville, Victoria, Australia

  • Holland Bloorview Kids Rehabilitation Hospital

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.